Health care resource utilization preceding death or lung transplantation in people with cystic fibrosis: HCRU before transplant or death in cystic fibrosis.

Autor: Guyot E; PELyon, PharmacoEpidémiologie Lyon, 210 avenue Jean Jaurès, 69007 Lyon, France. Electronic address: erika.guyot@pelyon.fr., Reynaud Q; RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France; French National Cystic Fibrosis Reference Center (constitutif), Service de médecine interne et de pathologie vasculaire, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Bénite, France; ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany., Belhassen M; PELyon, PharmacoEpidémiologie Lyon, 210 avenue Jean Jaurès, 69007 Lyon, France., Bérard M; PELyon, PharmacoEpidémiologie Lyon, 210 avenue Jean Jaurès, 69007 Lyon, France., Dehillotte C; Association Vaincre la Mucoviscidose, 181 Rue de Tolbiac, 75013 Paris, France., Lemonnier L; Association Vaincre la Mucoviscidose, 181 Rue de Tolbiac, 75013 Paris, France., Viprey M; RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France; Département des Données de Santé, Hospices Civils de Lyon, 162 avenue Lacassagne 69003 Lyon, France., Van Ganse E; RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France; Service de Pneumologie, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, 103 Grande Rue de la Croix-Rousse, 69002 Lyon, France., Burgel PR; ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany; Université ParisCité, Inserm U1016, Institut Cochin, Paris, France; Department of Respiratory Medicine and French National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Durieu I; RESearch on HealthcAre PErformance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France; French National Cystic Fibrosis Reference Center (constitutif), Service de médecine interne et de pathologie vasculaire, Hospices Civils de Lyon, Hôpital Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Bénite, France; ERN-Lung Cystic Fibrosis Network, Frankfurt, Germany.
Jazyk: angličtina
Zdroj: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2024 Sep; Vol. 23 (5), pp. 903-909. Date of Electronic Publication: 2024 Mar 12.
DOI: 10.1016/j.jcf.2024.03.001
Abstrakt: Background: We studied the health care resource utilization (HCRU) and associated costs in the year preceding LT in pwCF or death without LT, and we estimated the overall cost of LT.
Methods: We performed a linkage between 2006 and 2017 data from the French CF Registry (FCFR) and the French health claims database (Système National des Données de Santé; SNDS). The HCRU and associated costs were described the year before LT or before death without LT, and two years after LT.
Results: Among the 7,671 patients included in the FCFR, 6,187 patients (80.7 %) were successfully matched to patients in the SNDS (males (m): 51.9 %, mean±SD age at the end of follow-up: 24.6 ± 13.6). Overall, 166 patients died without LT (m: 47.6 %, age at death: 30.4 ± 14.5) and 767 patients with primary LT (m: 48.2 %, age at transplantation: 28.0 ± 9.1) were identified. HCRU was lower among patients who died without receiving LT, with marked differences in the cost of hospital stays. The mean total cost per patient was €66,759 ± 38,249 in the year before death, €149,374 ± 62,678 in the year preceding LT, €63,919 ± 35,399 in the first year following LT, and €42,813 ± 39,967 in the second year of follow-up.
Conclusion: Our results indicate that HCRU was two times lower in the year before death in non-transplant pwCF than in the year before LT, which may reflect inappropriate care of CF in patients who died without receiving LT. It also shows the cost associated with LT.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Isabelle Durieu reports financial support was provided by Vaincre la Mucoviscidose. Isabelle Durieu reports travel reimbursement was provided by Mylan. Eric Van Ganse reports financial support was provided by PELyon. Eric Van Ganse reports a relationship with PELyon that includes: consulting or advisory. Eric Van Ganse reports a relationship with AstraZeneca that includes: travel reimbursement. Marie Viprey reports a relationship with EPI-PHARE that includes: funding grants. Pierre-Régis Burgel reports a relationship with GSK that includes: consulting or advisory and funding grants. Pierre-Régis Burgel reports a relationship with Vertex that includes: consulting or advisory and funding grants. Pierre-Régis Burgel reports a relationship with AstraZeneca that includes: consulting or advisory and travel reimbursement. Pierre-Régis Burgel reports a relationship with Chiesi that includes: consulting or advisory and travel reimbursement. Pierre-Régis Burgel reports a relationship with Insmed that includes: consulting or advisory. Pierre-Régis Burgel reports a relationship with Viatris that includes: consulting or advisory. Pierre-Régis Burgel reports a relationship with Zambon that includes: consulting or advisory. M. Belhassen, M. Bérard, and E. Guyot are full-time employees of PELyon. C. Dehillotte, L. Lemonnier and Q. Reynaud have nothing to disclose.
(Copyright © 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: